abstract |
Met inhibitors and / or nucleotide sequences encoding them for use in the treatment of cancer patients to reduce and / or abolish the patient's resistance to radiation therapy, wherein the Met inhibitor is selected from: i) anti-Met monoclonal An antibody, ii) a genetically engineered antibody comprising the complementarity determining regions (CDRs) of an anti-Met monoclonal antibody, and iii) (i) comprising the complementarity determining regions (CDRs) of an anti-Met monoclonal antibody. fragment of (ii), or combinations thereof. |